Novartis says Kymriah demonstrates consistent efficacy, safety outcomes
Novartis announced results from two analyses of real-world experience with Kymriah, the only CAR-T cell therapy approved in two distinct indications. These analyses are from a readout of a 15-year post-marketing study that add to and complement the rigor of the Kymriah pivotal trials with evidence of the Kymriah real-world experience in expanded groups of patients. When Kymriah was used in the real-world setting, efficacy and safety were consistent when compared to the pivotal trials, including the 24-month analysis of JULIET in adults with r/r diffuse large B cell lymphoma and ELIANA in children and young adults with r/r B-cell acute lymphoblastic leukemia 1-6. The real-world experience data were presented at the 61st American Society of Hematology, or ASH, annual meeting.